Managing suicide risk in patients with schizophrenia

CNS Drugs

Volumn 25, Issue 2, 2011, Pages 129-143

  Kasckow, John ^a,b   Felmet, Kandi ^a   Zisook, Sidney ^c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antipsychotics, therapeutic use; Clozapine, therapeutic use; Depression; Schizophrenia; Serotonin uptake inhibitors, therapeutic use; Suicide

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

CLINICAL ASSESSMENT; DEMOGRAPHY; DEPRESSION; HUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW; RISK FACTOR; RISK REDUCTION; SCHIZOPHRENIA; STAFF TRAINING; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE;

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; SOCIAL SUPPORT; SUICIDE;

EID: 78951484731     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11586450-000000000-00000     Document Type: Review

References (132)

1. Allebeck P, Wistedt B. Mortality in schizophrenia: a ten-year follow-up based on the Stockholm County inpatient register. Arch Gen Psychiatry 1986; 43: 650-3
2. Montross L, Zisook S, Kasckow JW. Suicide among patients with schizophrenia: a consideration of risk and protective factors. Ann Clin Psychiatry 2005; 17: 173-82
3. Inskip HM, Harris EC, Barraclough B. Lifetime risk of suicide for affective disorder, alcoholism and schizophrenia. Br J Psychiatry 1998; 172: 35-7
4. Harris EC, Barraclough B. Suicide as an outcome for mental disorders: a meta-analysis. Br J Psychiatry 1997; 170: 205-28
5. Nasrallah HA, Smeltzer DJ. Contemporary diagnosis and management of the patient with schizophrenia. Newton (PA): Handbooks in Health Care, 2002
6. Breier A, Schreiber JL, Dyer J, et al. National Institute of Mental Health longitudinal study of chronic schizophrenia: prognosis and predictors of outcome. Arch Gen Psychiatry 1991; 48: 239-46
7. Roy A. Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatr Clin North Am 1986; 9: 193-206
8. Drake RE, Gates C, Whitaker A, et al. Suicide among schizophrenics: a review. Compr Psychiatry 1985; 26: 90-100
9. Miles CP. Conditions predisposing to suicide: a review. J Nerv Ment Dis 1977; 164: 231-46
10. Meltzer HY. Suicide and schizophrenia: clozapine and the InterSePT study. J Clin Psychiatry 1999; 60: 47-50
11. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005; 62: 247-53
12. Heila H, Isometsa ET, Henriksson MM, et al. Suicide and schizophrenia: a nationwide psychological autopsy study on age-and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 1997; 154: 1235-42
13. Kreyenbuhl JA, Kelly DL, Conley RR. Circumstances of suicide among individuals with schizophrenia. Schizophr Res 2002; 58: 253-61
14. Allebeck P, Varla A, Kristjansson E, et al. Risk factors for suicide among patients with schizophrenia. Acta Psychiatr Scand 1987; 76: 414-9
15. Caldwell CB, Gottesman II. Schizophrenia: a high risk factor for suicide: clues to risk reduction. Suicide Life Threat Behav 1992; 22: 479-93
16. Roy A. Suicide in schizophrenia. Int Rev Psychiatry 1992; 4: 205-9
17. Modestin J, Zarro I, Waldvogel D. A study of suicide in schizophrenic in-patients. Br J Psychiatry 1992; 160: 398-401
18. Cannon M, Buckley P, Larkin C. Suicide in schizophrenia. Irish J Psychol Med 1991; 8: 19-21
19. Cheng KK, Leung CM, Lo W, et al. Risk factors of suicide among schizophrenics. Acta Psychiatr Scand 1990; 81: 220-4
20. Tandon R, Jibson MD. Suicidal behavior in schizophrenia: diagnosis, neurobiology, and treatment implications. Curr Opin Psychiatry 2003; 16: 193-7
21. Cotton PG, Drake RE, Gates C. Critical treatment issues in suicide among schizophrenics. Hosp Community Psychiatry 1985; 36: 534-6
22. Pinikahana J, Happell B, Keks NA. Suicide and schizophrenia: a review of literature for the decade (1990-1999) and implications for mental health nursing. Issues Ment Health Nurs 2003; 24: 27-43
23. De Hert M, McKenzie K, Peuskens J. Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr Res 2001; 47: 127-34
24. Siris SG. Suicide and schizophrenia. J Psychopharmacol 2001; 15: 127-35
25. Raymont V. Suicide in schizophrenia: how can research influence training and clinical practice? Psychiatr Bull 2001; 25: 46-50
26. Roy A. Suicide in chronic schizophrenia. Br J Psychiatry 1982; 141: 171-7
27. Gut-Fayand A, Dervaux A, Olie JP, et al. Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Res 2001; 102: 65-72
28. Rossau CD, Mortensen PB. Risk factors for suicide in patients with schizophrenia: nested case-control study. Br J Psychiatry 1997; 171: 355-9
29. McGlashan TH, Carpenter WT. Postpsychotic depression in schizophrenia. Arch Gen Psychiatry 1976; 3: 231-9
30. Siris SG, Addington D, Azorin JM, et al. Depression in schizophrenia: recognition and management in the USA. Schizophr Res 2001; 47: 185-97
31. Pompili M, Mancinelli I, Tatarelli R. Suicide and schizophrenia. Psychiatr Serv 2003; 54: 747-8
32. Henriksson MM, Marttunen MJ, Isometsa ET, et al. Mental disorders in elderly suicide. Int Psychogeriatr 1995; 7: 275-86
33. Conwell Y, Duberstein PR, Cox C, et al. Relationships of age and axis I diagnoses in victims of completed suicide: a psychological autopsy study. Am J Psychiatry 1996; 153: 1001-8
34. Altamura AC, Bassetti R, Bignotti S, et al. Clinical vari-ables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 2003; 60: 47-55
35. Breier A, Astrachan BM. Characterization of schizophrenic patients who commit suicide. Am J Psychiatry 1984; 141: 206-9
36. Cohen LJ, Test MA, Brown RL. Suicide and schizophrenia: data from a prospective community treatment study. Am J Psychiatry 1990; 147: 602-7
37. Andia AM, Zisook S, Heaton RK, et al. Gender differences in schizophrenia. J Nerv Ment Dis 1995; 183: 522-8
38. Copas JB, Robin A. Suicide in psychiatric in-patients. Br J Psychiatry 1982; 141: 503-11
39. Black D, Winokur G, Warrach G. Suicide in schizophrenia: the Iowa Linkage Study. J Clin Psychiatry 1985; 46: 14-7
40. Caldwell CB, Gottesman II. Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 1990; 16: 571-89
41. Evenson RC, Wood JB, Nuttall EA, et al. Suicide rates among public mental health patients. Acta Psychiatr Scand 1982; 66: 254-64
42. Waern M, Runeson BS, Allebeck P, et al. Mental disorder in elderly suicides: a case-control study. Am J Psychiatry 2002; 159: 450-5
43. Mamo D. Caring for the suicidal patient: an evidence-based approach. Can J Psychiatry 2007; 52 Suppl. 1: 59S-70S
44. Nordentoft M. Prevention of suicide and attempted suicide in Denmark: epidemiological studies of suicide and intervention studies in selected risk groups. Dan Med Bull 2007; 54: 306-69
45. Nordentoft M, Jeppesen P, Abel M, et al. OPUS study: suicidal behaviour, suicidal ideation and hopelessness among patients with first-episode psychosis: one-year follow-up of a randomised controlled trial. Br J Psychiatry 2002; 43 Suppl.: s98-106
46. Pompili M, Mancinelli I, Girardi P, et al. Nursing schizophrenic patients who are at risk of suicide. J Psychiatr Ment Health Nurs 2003; 10: 622-4
47. Farberow N, Shneidman E, Neuringer C. Case history and hospitalization factors in suicides of neuropsychiatric hospital patients. J Nerv Ment Dis 1966; 142: 32-44
48. Morgan HG, Priest P. Assessment of suicide risk in psychiatric in-patients. Br J Psychiatry 1984; 145: 467-9
49. Morgan HG, Priest P. Suicide and other unexpected deaths among psychiatric in-patients: the Bristol confidential inquiry. Br J Psychiatry 1991; 158: 368-74
50. Crammer JL. The special characteristics of suicide in hos-pital in-patients. Br J Psychiatry 1984; 145: 460-3
51. Goh SE, Salmons PH, Whittington RM. Hospital suicides: are there preventable factors? Profile of psychiatric hospital suicide. Br J Psychiatry 1989; 154: 247-9
52. Saarinen PI, Lehtonen J, Lonnqvist J.Suicide risk in schizophrenia: an analysis of 17 consecutive suicides. Schizophr Bull 1999; 25: 533-42
53. De Leo D, Spathonis K. Do psychosocial and pharmaco-logical interventions reduce suicide in schizophrenia and schizophrenia spectrum disorders? Arch Suicide Res 2003; 7: 353-74
54. Lauriello J, Lenroot R, Bustillo JR. Maximizing the syn-ergy between pharmacotherapy and psychosocial therapies for schizophrenia. Psychiatr Clin North Am 2003; 26: 191-211
55. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161 (2 Suppl.): 1-56
56. Lenroot R, Bustillo JR, Lauriello J, et al. Integrated treatment of schizophrenia. Psychiatr Serv 2003; 54: 1499-507
57. Grawe RW, Falloon IR, Widen JH, et al. Two years of continued early treatment for recent-onset schizophrenia: a randomised controlled study. Acta Psychiatr Scand 2006; 114: 328-36
58. Turkington D, Kingdon D, Turner T. Effectiveness of a brief cognitive-behavioural therapy intervention in the treatment of schizophrenia. Br J Psychiatry 2002; 180: 523-7
59. Tarrier N, Haddock G, Lewis S, et al. Suicide behaviour over 18 months in recent onset schizophrenic patients: the effects of CBT. Schizophr Res 2006; 83: 15-27
60. Bateman K, Hansen L, Turkington D, et al. Cognitive behavioral therapy reduces suicidal ideation in schizophrenia: results from a randomized controlled trial. Suicide Life Threat Behav 2007; 37: 284-90
61. Ponizovsky AM, Grinshpoon A, Levav I, et al. Life satisfaction and suicidal attempts among persons with schizophrenia. Compr Psychiatry 2003; 44: 442-7
62. Nyman AK, Jonsson H. Patterns of self-destructive behav-iour in schizophrenia. Acta Psychiatr Scand 1986; 73: 252-62
63. Drake RE, Bartels SJ, Torrey WC. Suicide in schizophrenia: clinical approaches. In: Williams R, Dalby JT, editors. Depression in schizophrenia. New York: Plenum Press, 1989: 153-69
64. Beck AT, Steer RA, Kovacs M, et al. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry 1985; 142: 559-63
65. Mueser KT, Berenbaum H. Psychodynamic treatment of schizophrenia: is there a future? Psychol Med 1990; 20: 253-62
66. Harkavy-Friedman JM, Nelson EA. Assessment and intervention for the suicidal patient with schizophrenia. Psychiatr Q 1997; 68: 361-75
67. Drake RE, Cotton PG. Depression, hopelessness and suicide in chronic schizophrenia. Br J Psychiatry 1986; 148: 554-9
68. Restifo K, Harkavy-Friedman JM, Shrout PE. Suicidal behavior in schizophrenia: a test of the demoralization hypothesis. J Nerv Ment Dis 2009; 197: 147-53
69. Haghighat R. A discourse for hope: on defenses against suicide in people with schizophrenia. New York: Nova Science Publishers, 2007: 189-213
70. Lee PW, Lieh-Mak F, Wong MC, et al. The 15-year out-come of Chinese patients with schizophrenia in Hong Kong. Can J Psychiatry 1998; 43: 706-13
71. Appleby L, Shaw J, Amos T, et al. Suicide within 12 months of contact with mental health services: national clinical survey. Br Med J 1999; 318: 1235-9
72. Schooler NR. Relapse prevention and recovery in the treatment of schizophrenia. J Clin Psychiatry 2006; 67 Suppl. 5: 19-23
73. Hawton K, Sutton L, Haw C, et al. Schizophrenia and suicide: systematic review of risk factors. Br J Psychiatry 2005; 187: 9-20 (Pubitemid 41002508)
74. Ward A, Ishak K, Proskorovsky I, et al. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin Ther 2006; 28: 1912-21
75. Bustillo J, Lauriello J, Horan W, et al. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry 2001; 158: 163-75
76. Cipriani A, Pretty H, Hawton K, et al. Lithium in the prevention of suicidal behaviour and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005; 162: 1805-19
77. Leucht S, Kissling W, McGrath J. Lithium for schizophrenia. Cochrane Database Syst Rev 2007; (3): CD003834
78. Winokur G, Tsuang M. The Iowa 500: suicide in mania, depression, and schizophrenia. Am J Psychiatry 1975 Jun; 132: 650-1
79. Axelsson R, Lagerkvist-Briggs M. Factors predicting suicide in psychotic patients. Eur Arch Psychiatry Clin Neurosci 1992; 241: 259-66
80. Meltzer HY. Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 2001; 932: 44-58; discussion 58-60
81. Ernst CL, Goldberg JF. Antisuicide properties of psycho-tropic drugs: a critical review. Harv Rev Psychiatry 2004; 12: 14-41
82. Cohen S, Leonard CV, Farberow NL, et al. Tranquilizers and suicide in the schizophrenic patient. Arch Gen Psychiatry 1964; 11: 312-21
83. Warnes H. Suicide in schizophrenics. Dis Nerv Syst 1968; 29 Suppl.: 35-40
84. Taiminen TJ, Kujari H. Antipsychotic medication and suicide risk among schizophrenic and paranoid inpatients: a controlled retrospective study. Acta Psychiatr Scand 1994; 90: 247-51
85. Taiminen TJ. Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatr Scand 1993; 87: 45-7
86. Palmer DD, Henter ID, Wyatt RJ. Do antipsychotic medications decrease the risk of suicide in patients with schizophrenia? J Clin Psychiatry 1999; 60 Suppl. 2: 100-3; discussion 111-6
87. Van Putten T, May RP. Akinetic depression in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101-7
88. Cem Atbasoglu E, Schultz SK, Andreasen NC. The re-lationship of akathisia with suicidality and depersonaliza-tion among patients with schizophrenia. J Neuropsychiatry Clin Neurosci 2001; 13: 336-41
89. Wilkinson G, Bacon NA. A clinical and epidemiological survey of parasuicide and suicide in Edinburgh schizophrenics. Psychol Med 1984; 14: 899-912
90. Johnson DA, Pasterski G, Ludlow JM, et al. The dis-continuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983; 67: 339-52
91. Heila H, Isometsa ET, Henriksson MM, et al. Suicide vic-tims with schizophrenia in different treatment phases and adequacy of antipsychotic medication. J Clin Psychiatry 1999; 60: 200-8
92. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997; 17: 407-18
93. Muller-Siecheneder F, Muller MJ, Hillert A, et al. Risper-idone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol 1998; 18: 111-20
94. Beasley Jr CM, Hamilton SH, Crawford AM, et al. Olan-zapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997; 7: 125-37
95. Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003 Jan; 60 (1): 82-91
96. Meltzer HY, Baldessarini RJ. Reducing the risk for suicide in schizophrenia and affective disorders. J Clin Psychiatry 2003; 64: 1122-9
97. Barak Y, Mirecki I, Knobler HY, et al. Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl) 2004; 175: 215-9
98. Khan A, Khan SR, Leventhal RM, et al. Symptom reduc-tion and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 2001; 158: 1449-54
99. Storosum JG, van Zwieten BJ, Wohlfarth T, et al. Suicide risk in placebo vs active treatment in placebocontrolled trials for schizophrenia. Arch Gen Psychiatry 2003; 60: 365-8
100. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: impact on risk-benefit assessment. Am J Psychiatry 1995; 152: 183-90
101. Spivak B, Roitman S, Vered Y, et al. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998; 21: 245-50
102. Walker AM, Lanza LL, Arellano F, et al. Mortality in current and former users of clozapine. Epidemiology 1997; 8: 671-7
103. Reid WH, Mason M, Hogan T. Suicide prevention effects associated with clozapine therapy in schizophrenia and schizoaffective disorder. Psychiatr Serv 1998; 49: 1029-33
104. Sernyak M, Desai R, Stolar M, et al. Impact of clozapine on completed suicide. Am J Psychiatry 2001; 158: 931-7
105. Potkin SG, Alphs L, Hsu C, et al. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. Biol Psychiatry 2003; 54: 444-52
106. Modestin J, Dal Pian D, Agarwalla P. Clozapine di-minishes suicidal behavior: a retrospective evaluation of clinical records. J Clin Psychiatry 2005; 66: 534-8
107. Hennen J, Baldessarini RJ. Suicidal risk during treatment with clozapine: a meta-analysis. Schizophr Res 2005; 73: 139-45
108. Tiihonen T, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374: 620-7
109. De Hert M, Correll C, Cohen D. Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisalof the FIN-11 study. Schizophr Res 2010; 117: 68-74
110. American Psychiatric Association practice guidelines for the assessment and treatment of patients with suicidal behaviors. Am J Psychiatry 2003; 160 Suppl. 11: 1-60
111. Kerwin R. Preventing suicide [letter]. Br J Psychiatry 2003 Apr; 182: 366
112. Miller AL, Hall CS, Buchanan RW, et al. The Texas med-ication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry 2004; 65: 500-8
113. Meltzer H. Suicide in schizophrenia: clozapine, the adop-tion of evidence-based medicine [commentary]. J Clin Psychiatry 2005; 66: 4
114. Meltzer HY. Treatment-resistant schizophrenia: the role of clozapine. Curr Med Res Opin 1997; 14: 1-20
115. Meltzer HY, Conley RR, De Leo D, et al. Intervention strategies for suicidality [audiograph]. J Clin Psychiatry 2003; 6: 1-16
116. Roy A, Pompili M. Management of schizophrenia with suicide risk. Psychiatr Clin N Am 2009; 32: 863-83
117. Kasckow J, Fellows I, Golshan S, et al. Treatment of sub-syndromal depressive symptoms in middle-age and older patients with schizophrenia: effect of age on response. Am J Geriatr Psychiatry 2010; 18: 853-7
118. Kasckow JW, Zisook S. Co-occurring depressive symp-toms in the older patient with schizophrenia. Drugs Aging 2008; 25: 631-47
119. Furtado VA, Srihari V, Kumar A. Atypical antipsychotics for people with both schizophrenia and depression. Schizophr Bull 2009; 35: 297-8
120. Treatment of schizophrenia 1999: the expert consensus guideline series. J Clin Psychiatry 1999; 60 Suppl. 11: 3-80
121. Kane J, Leucht S, Carpenter D. The expert consensus guideline series: optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64 Suppl. 12: 5-19
122. Siris SG, Morgan V, Fagerstrom R, et al. Adjunctive imipramine in the treatment of postpsychotic depression: a controlled trial. Arch Gen Psychiatry 1987; 44: 533-9
123. Siris SG, Bermanzohn PC, Mason SE, et al. Maintenance imipramine therapy for secondary depression in schizophrenia: a controlled trial. Arch Gen Psychiatry 1994; 51: 109-15
124. Silver H, Nassar A. Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add-on double-blind, placebocontrolled study. Biol Psychiatry 1992 Apr 1; 31 (7): 698-704
125. Addington D, Addington J, Patten S, et al. Double-blind, placebocontrolled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. Clin Psychopharmacol 2002; 22: 20-5
126. Buchanan RW, Kirkpatrick B, Bryant N, et al. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia. Am J Psychiatry 1996; 153: 1625-7
127. Goff DC, Midha KK, Sarid-Segalo, et al. A placebocontrolled trialof fluoxetine added to neuroleptic in patients with schizophrenia. Psychopharmacology 1995; 117: 417-23
128. Spina E, De Domenico P, Ruello C, et al. Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenia patients. Int Clin Psychopharmacol 1994; 9: 281-5
129. Salokangas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebocontrolled study. Acta Psychiatr Scand 1996; 94: 175-80
130. Vartiainen H, Tiihonen J, Putkonen A, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91: 348-51
131. Zisook S, Kasckow JW, Lanouette NM, et al. Augmenta-tion with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizo-affective disorder who have subthreshold depressive symptoms: a randomized controlled trial. J Clin Psychiatry 2010; 71: 915-22
132. Zisook S, Kasckow JW, Golshan S, et al. Citalopram augmentation for sub-syndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial. J Clin Psychiatry 2009; 70: 562-71